Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2007; 98(01): 8-15DOI: 10.1160/TH07-05-0343 Anniversary Issue Contribution Schattauer GmbH Thrombosis and haemostasis research: Stimulating, hard work and fun Authors Author Affiliations Margareta Blombäck 1 Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden Recommend Article Abstract Full Text PDF Download(opens in new window) References References 1 Mutt V, Blombäck M. Erik Jorpes-a pragmatic physiological clinical chemist. Selected topics in the History of Biochemistry: Personal Recollections VI. Compr Biochem 2000; 41: 363-389. 2 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443. 3 Blombäck B. Travels with fibrinogen. J Thromb Haemost 2006; 4: 1653-1660. 4 Blombäck B. Chapter 6: Journey with bleeding time factor. In: Stories of success. Personal Recollections. Compr Biochem. Vol. 45 211-258 Elsevier Science BV; 2008 5 Blombäck B. Studies on fibrinogen: its purification and conversion into fibrin. Acta Physiol Scand 1958; 43 (Suppl. 148) 1-51. 6 http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_pres.htm http://www.ki.seessaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1a.htm http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1b.htm 7 Blombäck M. Purification of antihemophilic globulin. I. Some studies on the stability of the antihemophilic globulin activity in fraction I-0 and a method for its partial separation from fibrinogen. Arkiv Kemi 1958; 12: 387-396. 8 Blombäck M. Studies on antihemophilic globulin. Acta Paediatrica 1958; 47 (Suppl114) 1-32. 9 Nilsson IM, Blombäck M, Blombäck B. von Willebrand’s disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-278. 10 Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med. Scand. 1957; 159: 35-57. 11 Blombäck M. Scientific visits to the Åland Islands. Haemophilia, 1999; 5 (Suppl. 02) 12-18. 12 Blombäck M, Blombäck B, Nilsson IM. Response to fractions in von Willebrand’s disease. The Hemophilicas University North Carolina Press; Chapel Hill: 1964. pp. 286-294. 13 von Willebrand EA. “Hereditär pseudohämofili”. Finska Läkaresällskapets Handlingar 1926; 67: 87-111. 14 Nilsson IM, Blombäck M, Jorpes E. et al. von Willebrand’s disease and its correction with human plasma fraction I-O. Acta Med Scand 1957; 159: 179-188. 15 Blombäck M. A human factor VIII concentrate (Fraction I-0). Handbook of Hemophilia. Chapter 33. Excerpta Medica. Amsterdam: 1975. pp. 493-512. 16 Blombäck M, Nilsson IM. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand 1958; 161: 301-321. 17 Nilsson IM, Blombäck M, Ramgren O. et al. Haemophilia in Sweden. II. Carriers of Haemophilia A and B. Acta Med Scand 1962; 171: 223-235. 18 Nilsson IM, Blombäck M, Ahlberg Å. Our experience in Sweden with prophylaxis on haemophilia. The Hemophiliacand his world. Proc Vth Congr Wld Fed Haemophilia. Montreal Bibl Haemat 1970; 34: 111-124. 19 Blombäck B. “Pehr Victor Edman: The solitary genius”. In: Selected topics in thehistory of Biochemistry: Personal Recollections VII. Compr Biochem 2003; 42: 103-135. 20 Blombäck B, Blombäck M, Gröndahl NJ. et al. Structure of fibrinopeptides - its relation to enzyme specificity and phylogeny and classification of species. Arkiv Kemi 1966; 25: 411-428. 21 Blombäck M, Blombäck B, Mammen EF. et al. Fibrinogen Detroit - a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218: 134-137. 22 Blombäck B, Blombäck M, Olsson P. et al. Synthetic peptides with anticoagulant and vasodilating activity. Scand Clin Lab Invest 1969; 107 (Suppl): 59-64. 23 Blombäck B, Blombäck M, Olsson P. et al. Förfarande för framställning av polypeptider med biologiska verkningar. Swedish Patent Application No 14557/67. 24 Svendsen L, Blombäck B, Blombäck M. et al. Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thromb Res 1972; 1: 267-278. 25 Blombäck M, Blombäck B, Claeson G. et al. Nya diagnostiskt användbara substrat med hög specificitet till trombinoch andra proteolytiska enzymer av typen peptidyl-peptid hydrolaser. Swedish Patent Application No 5757/72. 26 Blombäck M, Egberg N. Chromogenic peptide substrates in the laboratory diagnosis of clotting disorders. Haemostasis and Thrombosis. Edinburgh: Vol56, pp. 967-981 1986. 1987. 27 New Frontiers in Hemophilia Research XVth World Federation of Hemophilia Congress, Stockholm 1983. Scand J Haematology 1984; 33 (Suppl): 40. 28 Thorell L, Blombäck B. Purification of the factor VIII complex. Thromb Res 1984; 35: 431-450. 29 Hessel B, Jörnvall H, Thorell L. et al. Structure-function relationship of factor VIII complex studied by thioredoxin dependent disulfide reduction. Thromb Res 1984; 35: 637-651. 30 Thorell L, Blombäck M, Blombäck B. An in vivo study of a new factor VIII high purity preparation. Thromb Res 1983; 31: 375-385. 31 Heimburger N. Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate. Blut 1982; 44: 249-251. 32 Anvret M, Blombäck M, Lindstedt M. et al. Genetic and coagulation characterization of Swedish families with von Willebrand’s disease types I and III: New aspects of heredity. Human Genetics 1992; 89: 147-154. 33 Zhang ZP, Falk G, Blombäck M. et al. A single cytosine deletion in exon 18 of the von Willebrand factor geneis the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1: 767-768. 34 Zhang ZP, Lindstedt M, Falk G. et al. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand’s disease type III and I. Am J Hum Genet 1992; 51: 870-878. 35 Zhang Z. Characterization of the von Willebrand factor gene in von Willebrand disease types 1 and 3. Thesis, Karolinska Institutet 1995. 36 Nyman D, Eriksson AW, Blombäck M. et al. Recent investigations of the first bleeder family in Åland (Finland) described by von Willebrand. Thromb Haemost 1981; 45: 73-76. 37 Zhang ZP, Blombäck M, Nyman D. et al. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland Islands. Proc Natl Acad Sci USA 1993; 90: 7937-7940. 38 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538. 39 Fatah K, Hamsten A, Blombäck B. et al. Fibrin gel network characteristics and coronary heart disease: Relations to fibrinogen concentration, acute phaseprotein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135. 40 Williams S, Fatah K, Hjemdahl P. et al. Better increase in fibrin gel porosity by lowdose than intermediate dose acetylic acid. Eur Heart J 1998; 19: 1666-1672. 41 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50 year challenge. Nature Rev/ Drug Discov 2004; 3: 649-658. 42 Li N, He S, Blombäck M. et al. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscl Thromb Vasc Biol 2007; 27: 407-413. 43 Suontaka AM. Hemostatic changes in plasma for transfusion during preparation and storage. Thesis, Karolinska Institutet, Stockholm, Sweden 2006.
